Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis (NCT00124475) | Clinical Trial Compass
CompletedPhase 3
Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Germany1,035 participantsStarted 2004-12
Plain-language summary
The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Chronic hand dermatitis, all types including hyperkeratotic, vesicular, fingertip dermatitis
* Lasting for 6 months since initial diagnosis
* Rated severe
* Refractory to standard therapy including non-medicated therapy and avoidance of irritants and allergens
* Refractory to topical steroids
Exclusion Criteria:
* Female patients who are pregnant or want to become pregnant
* Female patients of child bearing potential who cannot use or will not commit to using two effective forms of contraception simultaneously
* Patients whose disease is adequately controlled by standard non-medicated therapy and standard corticosteroid therapy